The Life Science Rundown
The FDA Group
0
The Life Science Rundown is a podcast for professionals in the life sciences, produced by The FDA Group. It covers topics in regulatory affairs, quality assurance, and clinical research. The show discusses industry news, explores trends, and features interviews with expert guests.
Episodes
-
Handheld or Wearable? Aaron Mann on Where Large-Volume Subcutaneous Delivery Is Headed 05.11.2026 31mAre on-body wearable injectors the future of large-volume drug delivery, or will formulation and device advances keep creating alternatives? Aaron Mann, CEO of Windgap Medical joins Nick Capman to compare the approaches and explain where he thinks the line between handheld and wearable delivery will settle.In this episode:Why about 2 mL has historically pushed doses toward wearablesHow formulation, enzyme-assisted delivery, and device design compareThe advantages and trade-offs of enzyme-assisted approachesWhy the 3 to 10 mL range has become so importantWhat a recent wearable-to-autoinjector a... -
Pharma Tech Transfer Is Knowledge Transfer 26.10.2026 17mWhy does tech transfer remain so hard in pharma , even when every document is neatly in order? Paige Kane, PhD, CPIP, Associate Vice President of Technical Excellence & Transformation at CAI, has spent about 25 years on technology transfers for clinical and commercial supply, and earned a PhD studying exactly that question.She joins Nick Capman to talk about moving the knowledge a receiving site needs, not just the documents and processes.They discuss:Why tech transfer could happen by FedEx if documents held everythingThe difference between know-what and know-whyTreating risk assessments as kn... -
The Adoption Assumptions Hiding in Your Regulatory Strategy 20.10.2026 1h 3mCan the fastest path to FDA approval end up being the slowest path to market adoption? Holley Proctor Miller, Founder and President of Grey Matter Marketing, has spent more than two decades helping medtech companies get new products adopted, starting with the early days of surgical robotics.She and Nick Capman get into the adoption assumptions built into every regulatory pathway decision, why approval evidence and adoption evidence aren’t the same thing, and what regulatory, quality, and commercial leaders should decide together before a pathway is locked in.A few topics they get into:Why clea... -
Dr. Robert Califf on What It Will Take for GLP-1s to Become a Public Health Success 05.10.2026 33mWe're honored to welcome Dr. Robert Califf, two-time Commissioner of Food and Drugs and founding director of the Duke Clinical Research Institute, to The Life Science Rundown.Dr. Califf joins Nick Capman to talk about how GLP-1 therapies could become a true public health success, and what it will take to get there: affordability, equitable access, trustworthy information, and responsible regulation. He brings the perspective of a cardiologist, clinical trialist, and two-time FDA leader, and he closes on a note of genuine optimism about what this class of drugs may teach us.Some of what he cove... -
Is Your Biotech De-Risking or Just Delaying? 18.09.2026 34mWhat stops a promising platform from becoming an investable company? Kevin Walton, CEO of Baseimmune, has watched this from both sides, first as an investment banker and now running a 23-person biotech through a strategic pivot he led himself.He and Nick Capman get into beachhead decisions, why most preclinical teams run their experiments in the wrong order, how to keep a distributed team aligned when the CEO is an ocean away, and what investors actually weight when science, team, execution, and strategy are all on the table.Some of what comes up:Run the experiment that could kill the program... -
Reg Ops Has Been Kept in a Box. This Is the Way Out. 14.09.2026 24mAs the FDA takes its first steps toward receiving clinical data in real time, what happens to regulatory operations professionals? Carla Griffin, CEO of The Sugar Water Operations Team, argues that reg ops has been kept in too small a box for years and that this shift is the opening to change that.Carla and Nick Capman get into why the hardest adjustment is professional rather than technical, how to vet technology vendors who don't understand your regulations, and the three things reg ops professionals should do in the next twelve months.A few of Carla's key takeaways:Reg ops specialists are p... -
QA Is Not a Gate — It’s a Technical Partner, with Dr. Andrea Bell 01.09.2026 28mHow do biotech companies move QA from late-stage gatekeeper into an early, risk-appropriate technical partner? Dr. Andrea Bell, a VP and Global Head of Quality Assurance, breaks down what phase-appropriate quality looks like across the lifecycle and why the barriers to getting there are cultural rather than procedural.Andrea and Nick get into the real cost of late QA involvement, how risk-based rigor differs from uniform rigor, what makes a quality management review actually function, and how QA earns credibility with technical teams.A few of Andrea's key takeaways:Late QA involvement costs mo... -
Managing AI Risk Across Global Quality Systems 17.08.2026 32mHow do you manage AI risk across global quality systems while the tools change every week? Julio Salwen, SVP and Chief Quality Officer at MiniMed, brings 35 years in pharma, devices, and diagnostics to a conversation about governance, risk tolerance, and what quality leaders need to learn right now.Julio and Nick get into why building for the auditor is the wrong instinct, how to introduce AI where the risk is genuinely low, why one overreaction makes an organization risk-averse, and what regulators will expect from AI governance.A few of Julio's key takeaways:Regulatory confidence means decis... -
The Case for Engaging Regulatory Early 13.08.2026 22mMost companies bring in regulatory expertise when they're ready to file. Leland Keyt, VP of Regulatory Affairs and Quality Assurance at Apreo Health, makes the case that by then you've already absorbed costs you didn't need to, and explains what early regulatory partnership actually looks like in practice.Leland and Nick get into why risk tolerance is the thing that catches scaling companies, the hidden costs of rework beyond timeline, how regulatory input changes product decisions across geographies, and what regulators are scrutinizing more closely now.A few of Leland's key takeaways:Early m... -
Why Quality and R&D Default to Conflict (and How to Fix It) 06.08.2026 30mWhy do quality and R&D fall into adversarial roles even when both are working toward patient safety? Shawn Fuller, who spent 24 years at Surmodics and rose from regulatory manager to VP of Quality, Regulatory and Clinical Affairs, is candid about how both sides create the problem and what it takes to break the pattern.Shawn and Nick get into the learned behavior behind the roadblock stereotype, why quality's timeline never gets extended, the memo-to-file versus special 510(k) trade-off, and the difference between a compliance gatekeeper and a strategic risk advisor.A few of Shawn's key takeawa... -
Leading Through the AI Shift with ASQ's CEO Sid Bhatnagar 03.07.2026 49mA special one for us: we sat down with Sid Bhatnagar, CEO of ASQ, the American Society for Quality. Sid is an engineer and longtime technology executive who now leads the global body at the center of the quality profession, and he brought a sharp, practical view of how AI is reshaping what leadership requires.Sid and Nick get into why AI pressure now comes from boards and investors rather than the ground up, how to keep human judgment on both ends of the process, what executives owe their people through the change, and how to think about ROI when the technology won't sit still.A few of the tak... -
Why Your CAPA System Isn't Driving Improvement (and How to Fix It) 15.06.2026 27mWhy do so many CAPA systems pass their metrics while the same problems keep coming back? Dan Eagles, a medical device quality VP and longtime CAPA mentor, breaks down where these systems quietly fail and how to rebuild them into tools that actually drive improvement.Dan discusses why the problem statement is where most CAPAs go wrong, how teams back-engineer root cause analysis to match a fix they've already chosen, and why "retrain the operator" is usually the wrong answer.A few of Dan's key takeaways:A closed CAPA that fails again for the same reason was never successful, repeat offenders ar... -
TerSera's VP of Quality on the Audit Risk Hiding Inside Your Own Procedures 18.05.2026 30mWhy do life science companies still scramble when an inspection is coming, even when their quality systems are solid on paper? Yeime Martich, a 25-year quality veteran, makes the case that readiness is a logistics and culture problem, not a documentation problem, and that the procedures you wrote may be creating more audit risk than you realize.Yeime discusses why "minimally compliant" is a discipline rather than a shortcut, how leadership shapes quality culture through what they ask about, fund, and tolerate, and why the strongest signal of a healthy quality system is when people come to qual... -
What Auditors Are Actually Looking For — and the Psychology Behind How They Find It 28.04.2026 19mWhy do audits still trigger panic even at companies with strong quality systems? Sneha Saggurthi — a quality compliance manager and lead auditor in cell therapy — breaks down the gap between being compliant and being audit ready, and shares the psychology, patterns, and logistics that actually determine inspection outcomes.Sneha discusses how auditors think and prioritize, why logistics matter more than most companies realize, and the specific psychological techniques auditors are trained to use — including how to handle them.A few of Sneha's key takeaways:Being compliant and being audit ready... -
Why Kidney Disease Innovation Is a Tale of Two Cities — and What It Would Take to Change That 10.04.2026 35mWhy are there over 400 phase three oncology programs but only one in dialysis? John Butler, who has spent over 30 years in the kidney disease space, breaks down the regulatory and reimbursement dynamics that have created a surge of innovation in rare kidney diseases while leaving dialysis patients behind, and what it would take to change that.John discusses how FDA clarity on endpoints transformed the rare kidney disease investment landscape, why the dialysis bundle makes innovation functionally impossible for providers, and how the Kidney Care Access Protection Act could be the first meaningf... -
Syncing Global Regulatory Filings Across FDA, EMA, and PMDA with AJ Acker 30.03.2026 28mWhat does it actually take to navigate global regulatory filings across the FDA, EMA, and PMDA, and why do so many programs stumble despite technically harmonized dossiers? AJ Acker draws on about 30 years of rare disease regulatory experience to break down the real differences between regions and the strategies that drive successful multi-regional approvals.AJ discusses why ICH compliance doesn't equal regulatory alignment, how Japan's evolving regulatory landscape creates both opportunity and complexity, and why the preparation that starts early in development (not at submission) is what det... -
Navigating Regulatory Leadership Across Large and Small Life Science with Tammy Sarnelli 19.03.2026 32mWhat actually changes for regulatory leaders when they move between large pharma and small biotech, and what stays the same? Tammy Sarnelli draws on over 35 years of experience across organizations of every size to break down the real differences in workload, risk tolerance, resource access, and culture.Tammy discusses how organizational silos create friction in large companies, why limited resources at small companies can actually accelerate decision-making, and how risk tolerance shapes not just strategy but the speed at which products move forward, especially in rare disease.A few of Tammy'... -
Getting Data Governance for Regulatory Submissions Right Before AI Gets it Wrong with Cary Smithson 05.03.2026 28mHow should life science companies govern their data to meet increasingly structured regulatory submission requirements and actually get value from AI? Cary Smithson shares lessons from decades of helping organizations modernize their regulatory, quality, and R&D operations.Cary discusses why data governance has become urgent across three fronts — structured submissions, cross-functional interoperability, and AI reliability — and walks through the foundational steps companies should take, the organizational challenges they'll hit, and what measurable results look like when governance is done ri... -
Building Resilient Biotech Teams in Cell and Gene Therapy with Nelly Viseux 09.02.2026 37mHow do you build an organization that can absorb change, learn from failure, and keep patients at the center—even when the science is uncertain? Nelly Viseux shares lessons from over 20 years in biotech and a decade leading cell and gene therapy development.Nelly discusses how she structured a 100-person CMC organization at Regeneron to balance innovation with operational execution, why documenting your assumptions is critical to managing risk, and what it really takes to maintain resilience when you're literally holding patient lives in your hands.A few of Nelly's key takeaways:Resilience is... -
Building Phase-Appropriate Quality from Preclinical to Commercial with Jackie Klecker 12.01.2026 35mScaling a product from preclinical development to commercial manufacturing is one of the most complex transitions life science teams face—and one of the easiest places to lose time and momentum.In this episode of The Life Science Rundown, host Nick Capman speaks with Jackie Klecker, Executive Vice President of Quality and Development Services at Lifecore Biomedical, about how sponsors and CDMOs can build robust, phase-appropriate quality systems without over-engineering early or under-preparing later.Drawing on decades of experience across pharmaceutical drug products, medical devices, APIs, a...
Popular in
The podcast also appears in the podcast charts of these countries.